|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  **L858R** **(n=59)** | **Exon 19 Deletion****(n=94)** | **Never Smoker****(n=95)** | **Ever Smokers****(n=58)** |
| **Median age (range)** |  64 (39-89) |  64 (29-87) |  64 (35-87) |  64 (24-89) |
| **Sex** **Female** **Male** |  38 (64%) 21 |  63 (67%)31  |  63 (66%) 32 |  38 (65%) 20  |
| **Smoking status** **Never** **Ever**  |  33 (56%) 26 |  62 (66%)32  |  NA |  NA |
| **Year EGFR-TKI Start** **2014 and earlier** **2015** **2016 - ongoing**  |  19 (32%)20 (34%)20 |  17 (18%)35 (37%)42 |  22 (23%)37 (39%)36 |  14 (24%)18 (31%)26 |
| **EGFR-TKI used** **Erlotinib** **Gefitinib**  **Afatanib**  |  55 (93%)-4 |  86 (91%)17 |  88 (93%)16 |  53 (91%)-5 |
| **Median TMB (range)** |  4.72 (0.82-17.92) | 3.17 (0.94-10.20) | 3.77 (0.82-10.66) | 4.09 (0.94-17.92) |